List of Excipients in Branded Drug FLONASE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Haleon US Holdings LLC	FLONASE	fluticasone propionate	0135-0576	BENZALKONIUM CHLORIDE
Haleon US Holdings LLC	FLONASE	fluticasone propionate	0135-0576	CARBOXYMETHYLCELLULOSE SODIUM
Haleon US Holdings LLC	FLONASE	fluticasone propionate	0135-0576	CELLULOSE, MICROCRYSTALLINE
Haleon US Holdings LLC	FLONASE	fluticasone propionate	0135-0576	DEXTROSE
Haleon US Holdings LLC	FLONASE	fluticasone propionate	0135-0576	PHENYLETHYL ALCOHOL
Haleon US Holdings LLC	FLONASE	fluticasone propionate	0135-0576	POLYSORBATE 80

FLONASE Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 24, 2026

Flonase is a fluticasone propionate nasal spray marketed in prescription and over-the-counter formats. Its commercial position rests on a mature active pharmaceutical ingredient, broad consumer recognition, established nasal-delivery technology, and a formulation that balances suspension stability, preservative control, spray performance, and tolerability. The largest opportunities are preservative-free delivery, improved sensory performance, pediatric usability, device differentiation, and private-label or regional licensing.

What is the active ingredient and formulation of Flonase?

Flonase contains fluticasone propionate, a synthetic corticosteroid administered as a nasal spray. The commonly marketed product delivers 50 micrograms of fluticasone propionate per spray. Fluticasone propionate is practically insoluble in water, so Flonase is formulated as an aqueous suspension rather than a true solution.[1]

The formulation uses excipients to maintain particle dispersion, preserve microbiological quality, control viscosity, and deliver a reproducible spray plume.

Component	Role in the Flonase formulation
Microcrystalline cellulose	Suspending and viscosity-building agent
Carboxymethylcellulose sodium	Suspending agent and rheology modifier
Dextrose	Tonicity and formulation-support excipient
Polysorbate 80	Wetting and dispersion aid
Benzalkonium chloride	Antimicrobial preservative
Phenethyl alcohol	Preservative and formulation-support component
Purified water	Vehicle

The exact excipient profile can vary by product presentation, market, manufacturing site, and labeling generation. The FDA-approved label and current commercial package insert control the legally relevant composition.[1]

How does the Flonase suspension system work?

Microcrystalline cellulose and carboxymethylcellulose sodium create a structured vehicle that keeps fluticasone particles dispersed during storage. The system must remain fluid enough to pass through the pump while recovering sufficient structure between uses to reduce rapid settling.

Polysorbate 80 improves wetting of the hydrophobic drug particles. Without effective wetting, the suspension can show agglomeration, inconsistent dose delivery, or poor redispersibility.

The formulation must also tolerate normal consumer handling. Shaking instructions, pump priming, storage orientation, actuation force, and nozzle cleanliness all affect delivered dose performance.

What excipients are protected by Flonase patents?

The core Flonase composition is a mature technology, and broad composition-of-matter protection for fluticasone propionate has expired. Commercial protection is more likely to arise from formulation combinations, suspension rheology, pump architecture, manufacturing controls, or an improved delivery profile than from the individual excipients themselves.

Which formulation elements have patent value?

Potentially protectable elements include:

• Defined ratios of microcrystalline cellulose and carboxymethylcellulose sodium.
• Particle-size distributions for fluticasone propionate.
• Suspension viscosity and yield-stress ranges.
• Preservative systems that maintain microbial control while reducing irritation.
• Pump and actuator designs that improve dose uniformity.
• Nozzle geometries that reduce throat deposition or post-use dripping.
• Manufacturing processes that control agglomeration and settling.
• Unit-dose or preservative-free packaging.
• Formulations that improve plume geometry or nasal deposition.

A patent claim directed only to a conventional excipient, such as polysorbate 80 or benzalkonium chloride, would generally face substantial prior-art exposure. Stronger claims are more likely to combine measurable formulation parameters with a demonstrated performance benefit.

When does Flonase lose exclusivity?

Flonase has already lost primary small-molecule exclusivity in the United States. Generic fluticasone propionate nasal sprays have been approved through the Abbreviated New Drug Application pathway.

The original prescription product was approved as Flonase Nasal Spray under NDA 020121. The current commercial position is therefore based on brand equity, over-the-counter access, distribution, consumer advertising, and product differentiation rather than active-ingredient exclusivity.[1][2]

Exclusivity component	Current position
Fluticasone propionate active-ingredient exclusivity	Expired
Prescription generic access	Established
OTC brand position	Commercially active
Biosimilar exclusivity	Not applicable
Formulation and device protection	Potentially relevant, but must be assessed by product and jurisdiction
Consumer brand protection	Trademark and trade dress remain relevant

The OTC switch changed the competitive framework. OTC Flonase Allergy Relief is marketed directly to consumers and is not dependent on a conventional prescription-generic substitution model. The brand competes through shelf placement, advertising, packaging, consumer trust, symptom coverage, and perceived ease of use.

What is the FDA regulatory status of Flonase?

Flonase is an FDA-approved intranasal corticosteroid. Flonase Allergy Relief is an OTC product used for the temporary relief of allergy symptoms, including nasal congestion, sneezing, runny nose, and itchy or watery eyes, subject to its approved labeling.[1]

The regulatory pathway differs by presentation:

Product type	Regulatory pathway
Prescription Flonase	NDA
OTC Flonase Allergy Relief	OTC switch and FDA-approved labeling
Generic fluticasone propionate nasal spray	ANDA
New preservative-free or device-modified product	Potentially an NDA supplement, 505(b)(2), or other FDA pathway depending on the change

A material excipient change can trigger more than a simple manufacturing variation. The regulatory burden depends on whether the change affects identity, strength, quality, purity, stability, microbial control, delivered dose, spray content uniformity, or clinical performance.

What Orange Book listings and Paragraph IV risks affect Flonase?

The original Flonase NDA has been subject to the normal small-molecule patent and exclusivity lifecycle. Current generic competition demonstrates that the principal product is no longer insulated from ANDA entry.

For an active or future Flonase-related product, Paragraph IV risks would most likely arise from patents covering:

1. A modified formulation.
2. A new nasal delivery device.
3. A preservative-free container-closure system.
4. A specific method of treating allergic rhinitis.
5. Manufacturing controls tied to particle size or dose uniformity.

A generic applicant can challenge listed patents through Paragraph IV certification. The commercial effect depends on the patent’s listing status, enforceability, claim scope, litigation timing, and whether the challenged claims cover the ANDA product.

For a mature fluticasone propionate nasal spray, the principal generic-entry risk is already realized. For a differentiated Flonase successor, patent listing strategy would become more important.

How strong is the Flonase patent estate?

The original Flonase patent estate is commercially weak against standard generic entry because the active ingredient and basic dosage form are mature. The remaining strategic value is concentrated in formulation and device know-how rather than broad exclusivity.

Patent category	Relative strategic strength
Fluticasone propionate composition of matter	Low due to expiry
Conventional aqueous suspension	Low to moderate
Specific excipient ratios	Moderate if tied to performance data
Spray pump and actuator	Moderate
Preservative-free presentation	Moderate to strong if technically differentiated
Manufacturing process	Moderate, with enforcement challenges
Method-of-use claims	Variable and often narrow
Brand, packaging, and trade dress	Commercially meaningful but not pharmaceutical exclusivity

Formulation patents are strongest when they claim a technically defined product that produces a measurable result, such as improved dose uniformity after storage, reduced settling, improved nasal deposition, reduced drip, or improved tolerability.

What excipient strategies could create new Flonase commercial opportunities?

1. Preservative-free Flonase

Benzalkonium chloride is effective and familiar, but its use in chronic intranasal products can create consumer and clinician concern regarding irritation or mucosal effects. A preservative-free version could target frequent users, pediatric populations, and consumers seeking a gentler formulation.

The commercial challenge is packaging. A multidose preservative-free system needs a container and pump that limit microbial ingress. Unit-dose packaging can reduce preservative requirements but raises cost, packaging volume, and convenience issues.

Potential IP targets include:

• Multidose sterile or microbiologically controlled pumps.
• One-way valve systems.
• Airless or barrier container designs.
• Preservative-free suspension stability.
• Unit-dose nasal spray systems.

2. Reduced-drip and improved-sensory formulations

Consumers frequently judge nasal products by aftertaste, throat runoff, nasal burning, and post-dose dripping. Excipient changes can alter viscosity, surface tension, wetting, and deposition.

A commercially valuable formulation would seek to:

• Reduce posterior drainage.
• Limit throat taste.
• Minimize nozzle blockage.
• Improve spray softness.
• Maintain consistent dosing after repeated use.

These benefits can support premium pricing if confirmed through human-factors studies and consumer testing.

3. Pediatric and family-use formulations

The active ingredient and strength may remain unchanged while the product is improved for children through:

• Lower actuation force.
• Smaller or more comfortable nozzle geometry.
• Clearer dose counters.
• Easier priming.
• Reduced residual volume.
• Packaging that supports caregiver administration.

The excipient system must remain compatible with pediatric labeling and accepted exposure limits. A pediatric strategy can also support licensing to regional consumer-health companies with established family-care distribution.

4. Improved suspension robustness

A mature product can still generate value through manufacturing and stability improvements. Useful targets include:

• Faster redispersion after prolonged storage.
• Reduced sediment compaction.
• Better delivered-dose uniformity near container exhaustion.
• Lower sensitivity to temperature excursions.
• More consistent particle distribution.
• Reduced pump clogging.

These improvements may support process patents, manufacturing know-how, or confidential technical information. Trade-secret protection can be more practical than patent protection for certain process controls.

5. Sustainability-oriented excipients and packaging

The strongest sustainability opportunity is likely to involve the delivery system rather than replacing the active ingredient. Candidates include lower-material packaging, recyclable components, reduced secondary packaging, and manufacturing processes with lower solvent or water consumption.

Any packaging change must preserve suspension stability, preservative performance, container-closure integrity, and pump-dose accuracy. Environmental claims also require substantiation under applicable advertising and consumer-protection rules.

Which companies compete with Flonase?

Flonase competes in the intranasal corticosteroid market and the broader allergy-relief category.

Product	Active ingredient	Competitive relevance
Flonase	Fluticasone propionate	Established OTC and prescription brand
Generic fluticasone propionate	Fluticasone propionate	Price competition
Nasacort	Triamcinolone acetonide	Major OTC intranasal corticosteroid competitor
Rhinocort	Budesonide	OTC intranasal corticosteroid competitor
Nasonex	Mometasone furoate	Prescription and OTC market relevance depending on presentation
Dymista	Fluticasone propionate plus azelastine	Combination-product differentiation
Antihistamine nasal sprays	Various	Compete for rapid symptom relief and congestion treatment

Flonase has a formulation and brand advantage from long market exposure, but generic products can undercut price. Nasacort and Rhinocort compete directly for OTC shelf space. Combination products compete by offering corticosteroid and antihistamine activity in one product.

What generic launch risks exist for Flonase?

The principal generic risks are price erosion, retailer substitution, private-label expansion, and reduced prescription demand. Generic products can compete effectively when they match the reference product’s active ingredient, strength, dosage form, and performance requirements.

Brand defenses include:

• Consumer advertising.
• Retailer agreements.
• Packaging differentiation.
• Product bundles.
• Family-size and travel-size presentations.
• Preservative-free or premium variants.
• Digital adherence and education programs.
• New delivery devices.

A reformulated product must provide a meaningful user benefit. Minor excipient changes without a visible or measurable advantage are unlikely to justify a durable premium.

What are the licensing opportunities for Flonase excipient technology?

Licensing opportunities are strongest in four areas:

1. Preservative-free multidose nasal pumps.
2. Low-drip and improved-sensory suspension systems.
3. Pediatric nasal-delivery devices.
4. Regional manufacturing platforms for generic or private-label fluticasone products.

A platform license could combine formulation know-how, pump specifications, stability protocols, analytical methods, and manufacturing controls. The licensor would need to define ownership of improvements, territory, regulatory responsibility, minimum purchase obligations, and freedom-to-operate rights.

Haleon owns the consumer-health portfolio that includes Flonase following the separation of GSK’s consumer-health business. Separate product presentations and geographic rights can create different licensing and co-development opportunities.[3]

What is the revenue exposure of Flonase?

Flonase is a major consumer-health brand, but public corporate reporting does not consistently disclose standalone global Flonase revenue. Revenue exposure should therefore be assessed through category position, distribution, brand investment, market share, and the contribution of OTC nasal allergy products within Haleon’s portfolio rather than through a consistently reported product-level figure.[3]

The commercial value of excipient innovation depends on whether it can produce one or more of the following:

• A premium OTC SKU.
• Lower manufacturing cost.
• Longer shelf life.
• Improved consumer retention.
• Retailer exclusivity.
• A differentiated patent position.
• Expansion into pediatric or sensitive-user segments.

How does Flonase compare with other nasal corticosteroids?

Flonase has one of the most established consumer positions in the category, but it does not have an active-ingredient exclusivity advantage over generic fluticasone products.

Factor	Flonase	Nasacort	Rhinocort
Active ingredient	Fluticasone propionate	Triamcinolone acetonide	Budesonide
OTC presence	Strong	Strong	Strong
Generic pressure	High	High	High
Main differentiation	Brand recognition and broad allergy positioning	OTC category competition	Alternative corticosteroid profile
Excipient opportunity	Preservative-free, low-drip, device improvements	Similar	Similar
Patent leverage for legacy product	Limited	Limited	Limited

The competitive battleground is formulation experience, delivery performance, consumer tolerability, retail execution, and brand trust rather than basic corticosteroid pharmacology.

Key Takeaways

• Flonase uses a mature aqueous suspension system containing cellulose-based suspending agents, polysorbate 80, preservatives, dextrose, and purified water.
• Broad active-ingredient exclusivity has expired, and generic fluticasone propionate nasal sprays are established.
• The strongest new IP opportunities involve preservative-free delivery, pump architecture, spray performance, particle-size control, and manufacturing processes.
• Benzalkonium chloride reduction or elimination could support premium positioning, particularly for frequent users and pediatric consumers.
• Generic competition limits pricing power for the legacy product, while brand equity supports OTC resilience.
• A differentiated excipient or device platform could support licensing, private-label supply, or a successor product.
• Flonase does not face biosimilar competition because fluticasone propionate is a small molecule, not a biologic.
• Standalone Flonase revenue is not consistently reported publicly by Haleon, so exposure is best evaluated through category and portfolio metrics.

FAQs

Is Flonase a suspension or a solution?

Flonase is generally formulated as an aqueous suspension because fluticasone propionate has very low water solubility.

Does Flonase contain benzalkonium chloride?

The marketed Flonase formulation includes benzalkonium chloride as a preservative, together with phenethyl alcohol. Product-specific labeling should be used because formulations can vary by presentation and market.[1]

Can a preservative-free Flonase product receive patent protection?

Yes. Protection could cover the preservative-free formulation, container-closure system, multidose pump, microbial-control mechanism, or demonstrated delivery benefit. The patent must contain claims that are novel and non-obvious over existing nasal sprays.

Is generic Flonase available?

Yes. Generic fluticasone propionate nasal sprays are available in the United States through the ANDA pathway. Generic availability does not eliminate the commercial value of the Flonase OTC brand.

Is Flonase subject to biosimilar competition?

No. Fluticasone propionate is a small-molecule drug. Competitive products are generics, alternative nasal corticosteroids, combination products, and other allergy treatments.

References

1. U.S. Food and Drug Administration. (2023). Flonase Allergy Relief: Prescribing information and drug facts labeling.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. Haleon plc. (2024). Annual report and financial statements 2023.